Prolonged Grief Disorder: The Tug-of-War Over Medicalizing Mourning

Is it Time to Acknowledge PGD as a Distinct Medical Condition, or Does Doing So Medicalize a Universal Human Experience?

Prolonged Grief Disorder (PGD) is a term gaining traction in mental health circles, igniting an intense debate on the boundaries of medicalizing human emotions. Classified as an enduring, intense form of mourning, PGD affects those who find it challenging to resume a regular life after a loss. But as mental health professionals weigh the pros and cons of acknowledging PGD as a distinct diagnosis, society must question whether the path to understanding our emotional complexities should be a medicalized one.

PGD is no fringe condition. Estimates suggest that between 10 and 20 percent of those grieving a loss may be wrestling with the disorder. Symptoms are heartbreaking: a continuous yearning for the deceased, a preoccupation with the lost one to the exclusion of almost everything else, difficulty coming to terms with the loss, and an overwhelming sense of purposelessness.

The crux of the controversy is whether grief, a universally experienced emotion, should be classified as a disorder. Skeptics argue that doing so medicalizes a fundamentally human experience, one often necessary for emotional growth. “It’s like saying sadness or happiness could be conditions needing treatment,” notes Dr. Alice Thompson, a psychologist skeptical of the PGD diagnosis. Critics worry that if we label grief as a disorder, we risk pathologizing the natural, albeit painful, adaptive process.

On the flip side, advocates for recognizing PGD argue that it is a unique form of suffering necessitating specialized care. By acknowledging it as a distinct condition, clinicians can tailor specific therapeutic interventions. “We’re not trying to pathologize grief,” says Dr. John Williams, a proponent of PGD recognition. “We’re trying to identify when grief becomes so persistent and debilitating that it interferes with daily life.”

Tipping the scale in favor of its inclusion, the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) introduced Persistent Complex Bereavement Disorder (PCBD) in March 2022. The move, however, has not ended the conversation but has intensified the discourse among professionals. While some see the inclusion as a win for patient-centered care, others view it as a Pandora’s box, setting a precedent for medicalizing a wide array of human experiences.

The debate over PGD exemplifies a broader discussion in the healthcare industry: Where do we draw the line in medicalizing human emotions and experiences? While the recognition of PGD or PCBD in official medical manuals may provide solace and tailored treatments to some, it also prompts serious ethical questions about the potential for over-medicalization in mental health. Regardless of where one stands, the dialogue around PGD serves as a pressing reminder that as science advances, so too must our ethical considerations.